We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Benitec Biopharma Limited is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BNTC's full-year earnings has moved 57.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BNTC has gained about 14.1% so far this year. At the same time, Medical stocks have lost an average of 3.5%. This means that Benitec Biopharma Limited is outperforming the sector as a whole this year.
Concentra Group (CON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.9%.
For Concentra Group, the consensus EPS estimate for the current year has increased 3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Benitec Biopharma Limited belongs to the Medical - Biomedical and Genetics industry, a group that includes 508 individual companies and currently sits at #84 in the Zacks Industry Rank. On average, this group has lost an average of 3.3% so far this year, meaning that BNTC is performing better in terms of year-to-date returns.
On the other hand, Concentra Group belongs to the Medical Services industry. This 58-stock industry is currently ranked #77. The industry has moved -1.5% year to date.
Investors interested in the Medical sector may want to keep a close eye on Benitec Biopharma Limited and Concentra Group as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Benitec Biopharma Limited is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BNTC's full-year earnings has moved 57.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BNTC has gained about 14.1% so far this year. At the same time, Medical stocks have lost an average of 3.5%. This means that Benitec Biopharma Limited is outperforming the sector as a whole this year.
Concentra Group (CON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.9%.
For Concentra Group, the consensus EPS estimate for the current year has increased 3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Benitec Biopharma Limited belongs to the Medical - Biomedical and Genetics industry, a group that includes 508 individual companies and currently sits at #84 in the Zacks Industry Rank. On average, this group has lost an average of 3.3% so far this year, meaning that BNTC is performing better in terms of year-to-date returns.
On the other hand, Concentra Group belongs to the Medical Services industry. This 58-stock industry is currently ranked #77. The industry has moved -1.5% year to date.
Investors interested in the Medical sector may want to keep a close eye on Benitec Biopharma Limited and Concentra Group as they attempt to continue their solid performance.